Sied Kebir

L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial

The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue,⁶⁸Ga-FAPI-46 PET Data, and Survival Data

Predictors and surgical outcome of hemorrhagic metastatic brain malignancies

Telemedicine in Neuro-Oncology—An Evaluation of Remote Consultations during the COVID-19 Pandemic

KDM5B predicts temozolomide-resistant subclones in glioblastoma

Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma

Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed <i>MGMT</i> promoter methylated <i>IDH</i> wildtype glioblastoma

A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma

CTNI-29. INVESTIGATING SAFETY AND EFFICACY OF TTFIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA - FIRST RESULTS OF THE PRICOTTF PHASE I/II TRIAL

Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression

How about Levetiracetam in Glioblastoma? An Institutional Experience and Meta-Analysis

Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography

Dosimetric impact of the positioning variation of tumor treating field electrodes in the PriCoTTF‐phase I/II trial

Case Report: Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant Melanoma

Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice

A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma

Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial

Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma

Challenging Implications of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids Syndrome with an Atypical Presentation: Report of Two Cases

Abstract CT106: PriCoTTF trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors

Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma

Olfactory function as an independent prognostic factor in glioblastoma

Xenografting for disease modeling of intramedullary spinal cord tumors: a systematic review

P14.61 Tumor Treating Fields (TTFields) combined with lomustine (CCNU) and temozolomide (TMZ) in newly diagnosed glioblastoma (GBM) patients - a bi-centric analysis

Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report

Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial

RARE-39. COMBINATION OF TUMOR TREATING FIELDS (TTFIELDS) WITH LOMUSTINE (CCNU) AND TEMOZOLOMIDE (TMZ) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS - A BI-CENTRIC ANALYSIS